Resultado de búsqueda
2 de sept. de 2019 · The trial was stopped early because of increased mortality in the combination-therapy group. Rivaroxaban monotherapy was noninferior to combination therapy for the primary efficacy end point, with ...
19 de ene. de 2021 · In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, and aspirin ...
The AUGUSTUS trial design and results have been published.6 14 In brief, AUGUSTUS was an international, randomised, clinical trial with a 2-by-2 factorial design in which patients with AF and recent ACS and/or undergoing PCI and taking a P2Y12 inhibitor were factorially randomised to apixaban or VKA (open-label), and aspirin or aspirin placebo (double-blind) for 6 months.
L’AUGUSTUS trial. A cura di Sarah Cortinovis. È stato recentemente presentato all’American College of Cardiology e contemporaneamente pubblicato sull’ultimo numero del New England Journal of Medicine il tanto atteso AUGUSTUS, trial randomizzato e multicentrico sull’utilizzo di apixaban in pazienti con storia di fibrillazione atriale ...
26 de sept. de 2019 · The choice of antithrombotic therapy in patients with AF and ACS and/or undergoing PCI reflects the difficult balance between mitigating bleeding and reducing ischemic and thromboembolic risk. 17,18 The overall results of the AUGUSTUS trial and the results of these subgroup analyses support the use of apixaban, at the dose approved for stroke prevention in patients with AF, combined with P2Y ...
11 de sept. de 2019 · Of the population included in the AUGUSTUS trial, 1,714 (37.3%) had an ACS event as the reason for inclusion. In subgroup analyses, relative risk reductions of 56%, 32%, and 18% in the primary safety outcome favored apixaban over warfarin in patients with ACS who did not receive PCI, patients with ACS and PCI, and patients with elective PCI, respectively (P=0.052 for interaction).
3 de mar. de 2011 · Lopes, RD, Alexander, JH, Al-Khatib, SM, et al. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159 ...
